540222 Stock Overview Manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Laurus Labs Limited Competitors Price History & Performance
Summary of share price highs, lows and changes for Laurus Labs Historical stock prices Current Share Price ₹583.50 52 Week High ₹619.50 52 Week Low ₹358.70 Beta 1.12 1 Month Change 1.89% 3 Month Change 23.09% 1 Year Change 40.20% 3 Year Change 12.01% 5 Year Change 621.80% Change since IPO 507.18%
Recent News & Updates
Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025 Jan 06
First half dividend of ₹0.40 announced Oct 26
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Oct 25
Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025 Oct 24
Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 17
Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent Director Oct 03 See more updates
Laurus Labs Limited to Report Q3, 2025 Results on Jan 24, 2025 Jan 06
First half dividend of ₹0.40 announced Oct 26
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Oct 25
Laurus Labs Limited Approves Interim Dividend for the Financial Year 2024- 2025 Oct 24
Laurus Labs Limited to Report Q2, 2025 Results on Oct 24, 2024 Oct 17
Laurus Labs Limited Appoints Ramesh Subrahmanian as A Non-Executive Independent Director Oct 03
First quarter 2025 earnings: EPS and revenues miss analyst expectations Jul 26
Laurus Labs Limited to Report Q1, 2025 Results on Jul 25, 2024 Jul 22
Laurus Labs Limited Announces Board Appointments Jul 12
Full year 2024 earnings: EPS misses analyst expectations Jun 20
Less than half of directors are independent May 21
Final dividend reduced to ₹0.40 Apr 27
Laurus Labs Limited, Annual General Meeting, Jul 11, 2024 Apr 27
Full year 2024 earnings: EPS misses analyst expectations Apr 26 Laurus Labs Limited Approves Board Changes
Laurus Labs Limited to Report Q4, 2024 Results on Apr 25, 2024 Apr 19
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Jan 25
Laurus Labs Limited to Report Q3, 2024 Results on Jan 24, 2024 Jan 17
Upcoming dividend of ₹0.40 per share at 0.4% yield Oct 26
Price target increased by 7.2% to ₹371 Oct 24
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Oct 21 Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023
Laurus Labs Limited to Report Q2, 2024 Results on Oct 20, 2023 Oct 14
Laurus Labs Limited (NSEI:LAURUSLABS) agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million. Sep 12
Investor sentiment improves as stock rises 16% Aug 04
New minor risk - Profit margin trend Jul 28
First quarter 2024 earnings released: EPS: ₹0.46 (vs ₹4.68 in 1Q 2023) Jul 28
Full year 2023 earnings: EPS and revenues miss analyst expectations Jun 24
Laurus Labs Limited (NSEI:LAURUSLABS) signed an investment agreement to acquire additional 7.24% stake in Immunoadoptive Cell Therapy Private Limited for INR 800 million. Jun 01
Upcoming dividend of ₹1.20 per share at 0.6% yield May 03
Price target decreased by 11% to ₹382 Apr 30
Full year 2023 earnings: EPS and revenues miss analyst expectations Apr 28
Price target decreased by 10% to ₹470 Feb 01
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Jan 31
Laurus Labs Limited to Report Q3, 2023 Results on Jan 30, 2023 Jan 22 Laurus Labs Limited announced that it expects to receive INR 38.998 million in funding from Ethan Energy India Private Limited Nov 25
Price target decreased to ₹561 Nov 16
Insufficient new directors Nov 16
Consensus EPS estimates fall by 14% Oct 28
Upcoming dividend of ₹0.80 per share Oct 27
Price target decreased to ₹574 Oct 26
Laurus Labs Limited Approves Interim Dividend for the Financial Year 2022-2023, Payable on or After November 15, 2022 Oct 22
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Oct 22
Laurus Labs Limited to Report Q2, 2023 Results on Oct 21, 2022 Oct 14
First quarter 2023 earnings: EPS and revenues exceed analyst expectations Jul 28
Laurus Labs Limited to Report Q1, 2023 Results on Jul 27, 2022 Jul 20
Investor sentiment deteriorated over the past week Jun 20
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Jun 09
Upcoming dividend of ₹1.20 per share May 03
Full year 2022 earnings: Revenues and EPS in line with analyst expectations Apr 29
Insufficient new directors Apr 27
Laurus Labs Limited to Report Q4, 2022 Results on Apr 28, 2022 Apr 22
Consensus revenue estimates fall by 14% Feb 03
Price target decreased to ₹563 Feb 02
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Jan 28
Upcoming dividend of ₹0.80 per share Nov 10
Second quarter 2022 earnings released: EPS ₹3.76 (vs ₹4.53 in 2Q 2021) Nov 01
Investor sentiment deteriorated over the past week Oct 22
Insider recently sold ₹7.9m worth of stock Sep 22
Insider recently sold ₹3.2m worth of stock Sep 11
Insider recently sold ₹3.6m worth of stock Sep 04
Insider recently sold ₹1.0m worth of stock Aug 13
Price target increased to ₹561 Aug 04
First quarter 2022 earnings released: EPS ₹4.50 (vs ₹3.21 in 1Q 2021) Jul 30
Price target increased to ₹506 Jul 12
Laurus Labs Limited Receives the License to Manufacture and Market 2-Deoxy-D-Glucose (2DG) in India Jul 03
Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020) Jun 24
Insider recently bought ₹4.0m worth of stock May 23
Insider recently sold ₹35m worth of stock May 07
Consensus EPS estimates increase to ₹21.57 May 06
Price target increased to ₹430 May 05
Upcoming dividend of ₹0.80 per share May 04
Full year 2021 earnings released: EPS ₹18.36 (vs ₹4.79 in FY 2020) May 01
Laurus Labs Limited Approves Third Interim Dividend, Payable on or After May 19, 2021 Apr 30
Investor sentiment improved over the past week Apr 07
Insider recently sold ₹1.5m worth of stock Mar 10
Price target raised to ₹399 Feb 23
Insider recently sold ₹1.9m worth of stock Feb 21
Insider recently bought ₹3.0m worth of stock Feb 06
Revenue and earnings beat expectations Jan 30
Third quarter 2021 earnings released: EPS ₹5.09 (vs ₹1.38 in 3Q 2020) Jan 30
Laurus Labs Limited (BSE:540222) completed the acquisition of 72.55% stake in Richcore Lifesciences Pvt. Ltd. from VenturEast Proactive Fund and VenturEast Life Fund III, L.P. managed by Ventureast Fund Advisors India Limited and Eight Roads Ventures India. Jan 22
Laurus Labs Limited to Report Q3, 2021 Results on Jan 28, 2021 Jan 20
New 90-day high: ₹372 Jan 20
Insider recently sold ₹1.5m worth of stock Jan 07
New 90-day high: ₹359 Jan 04
Insider recently sold ₹1.2m worth of stock Dec 23
New 90-day high: ₹339 Dec 16
Insider recently sold ₹1.6m worth of stock Dec 08
Laurus Labs Limited (BSE:540222) signed a definitive agreement to acquire 72.6% stake in Richcore Lifesciences Pvt. Ltd. from VenturEast Proactive Fund and VenturEast Life Fund III, L.P. managed by Ventureast Fund Advisors India Limited and Eight Roads Ventures India for INR 2.5 billion. Nov 26
Insider recently bought ₹3.4m worth of stock Nov 12
Analysts increase revenue estimates to ₹44.5b Nov 05
Upcoming Dividend of ₹0.80 Per Share Nov 03
First half earnings released Oct 30
Second-quarter earnings released: Revenue beats expectations, earnings disappoint Oct 30 Shareholder Returns 540222 IN Pharmaceuticals IN Market 7D -4.5% -2.4% -3.3% 1Y 40.2% 32.1% 13.4%
See full shareholder returns
Return vs Market: 540222 exceeded the Indian Market which returned 13.4% over the past year.
Price Volatility Is 540222's price volatile compared to industry and market? 540222 volatility 540222 Average Weekly Movement 4.4% Pharmaceuticals Industry Average Movement 5.9% Market Average Movement 6.1% 10% most volatile stocks in IN Market 9.0% 10% least volatile stocks in IN Market 4.0%
Stable Share Price: 540222 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 540222's weekly volatility (4%) has been stable over the past year.
About the Company Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs.
Show more Laurus Labs Limited Fundamentals Summary How do Laurus Labs's earnings and revenue compare to its market cap? 540222 fundamental statistics Market cap ₹314.71b Earnings (TTM ) ₹1.31b Revenue (TTM ) ₹50.53b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 540222 income statement (TTM ) Revenue ₹50.53b Cost of Revenue ₹24.60b Gross Profit ₹25.93b Other Expenses ₹24.62b Earnings ₹1.31b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Jan 24, 2025
Earnings per share (EPS) 2.43 Gross Margin 51.32% Net Profit Margin 2.59% Debt/Equity Ratio 65.7%
How did 540222 perform over the long term?
See historical performance and comparison Dividends
0.1% Current Dividend Yield
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/10 20:04 End of Day Share Price 2025/01/10 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Laurus Labs Limited is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Prashant Nair Ambit Capital Nitin Bhasin Ambit Capital null null Antique Stockbroking Ltd.
Show 20 more analysts 
